GlobeNewswire by notified

Kitron: Q3 2020 - Record performance continues

Share

(2020-10-21) Kitron today reported strong growth and record profit for the third quarter driven by the Medical devices, Defence/Aerospace and Industry sectors.

Kitron's revenue for the third quarter was NOK 1 054 million, an increase of 43 per cent compared to last year. Growth adjusted for currency effects was 35 per cent.

Profitability expressed as EBIT margin was 8.6 per cent in the third quarter, compared to 5.4 per cent in the same quarter last year.

The order backlog ended at NOK 1 863 million, an increase of 18 per cent compared to last year.

Peter Nilsson, Kitron's CEO, comments:
"The strong performance in the first half of 2020 continues over the rest of the year.
A 43 per cent growth in the third quarter and revenue over NOK 1 billion is a record for Kitron.
The third quarter is characterized by exceptional revenues in medical devices. The remarkable performance of Kitron employees and partners has made this possible.
Extraordinary operational execution generated a solid EBIT margin of 8.6 per cent. Earnings per share is more than doubled compared to last year. Once again, we increase our full year outlook based on strong demand in several sectors.”

Record revenue
Kitron's revenue in the third quarter amounted to NOK 1 054 million, compared to 738 million in the same quarter last year. There was strong growth within the Defence/Aerospace and Industry sectors and very strong growth within the Medical devices sector.

Strong order backlog
The order backlog ended at NOK 1 863 million, compared to 1 572 million last year. The order backlog increased within all market sectors except Offshore/Marine. Growth is particularly strong in the Industry sector

Improved profitability
Third quarter operating profit (EBIT) was NOK 90.5 million, compared to 39.6 million last year. EBITDA was NOK 115.7 million, compared to 59.7 million last year. Profit after tax amounted to NOK 60.9 million, compared to 24.6 million in the same quarter the previous year. This corresponds to earnings per share of NOK 0.34, up from 0.14 last year.

The strong growth has challenged operational cash flow, which ended at negative NOK 3.2 million, compared to 19.2 million in the third quarter of 2019.

Capital efficiency ratios improved
Net working capital was NOK 1 134 million, an increase of 28 per cent compared to the same quarter last year. However, capital efficiency ratios improved. Cash conversion cycle improved from 116 days to 96 days, and net working capital as a percentage of revenue was 25.1 per cent, compared to 29.5 per cent last year. Capital ratios are expected to improve further.

Dividend distribution
After the end of the third quarter, and pursuant to the authorisation granted by the general meeting, the Board of Directors has resolved a dividend of NOK 0.50 per share (see separate stock exchange notice dated 20 October 2020 for further details).

Outlook
For 2020, Kitron has previously indicated a revenue outlook of between NOK 3 500 and 3 800 million and EBIT margin between 6.7 and 7.5 percent.

Due to increased growth in the Defence/Aerospace, Industry and Medical devices sectors, overall profitability improvement and favorable currency, revenue is now expected to be between NOK 3 850 and 4 000 million and EBIT margin is expected to be between 7.6 and 7.8 per cent.

As previously reported, demand within the Medical devices sector, driven by the Corona pandemic, has been particularly strong in the second and third quarter. This is expected to normalize in the fourth quarter and going forward.

Enclosed in PDF are the quarterly report and the presentation. The interim
report is presented today at 8:30 a.m. CEST. The presentation will be given in
English by CEO Peter Nilsson and CFO Cathrin Nylander, and will be webcast at
the following link:
https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20201021_1

For further information, please contact:
Peter Nilsson, President and CEO, tel. +47 94 84 08 50
Cathrin Nylander, CFO, tel: +47 900 43 284
E-mail: investorrelations@kitron.com

Kitron is a leading Scandinavian electronics manufacturing services company for the Defence/Aerospace, Energy/Telecoms, Industry, Medical devices and Offshore/Marine sectors. The company is located in Norway, Sweden, Lithuania, Germany, Poland, China and the United States. Kitron had revenues of about NOK 3.3 billion in 2019 and has about 1 700 employees. www.kitron.com

This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act. 

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Correction to Company announcement – No. 23 / 202419.4.2024 22:20:51 CEST | Press release

Correction to Company announcement – No. 23 / 2024 Copenhagen, Denmark, April 19, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has a correction to company announcement No. 23 /2024, April 19, 2024 - regarding transactions in Zealand’s shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons it was reported that member of the management, Henriette Wennicke, was allocated a total of 8,008 restricted stock units with a total value of DKK 9,577,568.00. The correct number was a total of 8,008 restricted stock units with a total value of DKK 4,788,784.00. Please see the attached file(s). # # # About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10

Nokia Corporation: Repurchase of own shares on 19.04.202419.4.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 19 April 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 19.04.2024 Espoo, Finland – On 19 April 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL430,8933.30CEUX--BATE--AQEU--TQEX--Total430,8933.30 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of

Landsbankinn hf.: Results of the 2024 AGM of Landsbankinn19.4.2024 20:48:08 CEST | Press release

The annual general meeting (AGM) of Landsbankinn, held on 19 April 2024, agreed to pay a dividend amounting to ISK 16,535 million to shareholders. The dividend is equivalent to 50% of 2023 profits. The dividend will be paid in two instalments, firstly on 24 April 2024 and secondly on 16 October 2024. As a result, total dividend paid by the Bank in 2013-2024 amounts to ISK 191.7 billion. At the AGM, held in Reykjastræti 6, Helga Björk Eiríksdóttir, Chairman of the Board of Directors, delivered the report from the Board for 2023. Lilja Björk Einarsdóttir, CEO, spoke of the Bank’s operation, strategy and activities in the past operating year. The annual financial statement for the past operating year was approved, as was the proposed Remuneration Policy and remuneration to Directors of the Board. The AGM elected the Auditor General (Ríkisendurskoðun) as auditor of Landsbankinn hf. for the 2024 operating year. The Auditor General, in accordance with an authorisation to outsource tasks, and

SKEL fjárfestingafélag hf.: Styrkás finalizes the purchase of Stólpi Gámar ehf. and affiliated companies.19.4.2024 19:20:57 CEST | Press release

Reference is made to the announcement dated 31 January 2024, regarding Styrkás hf., a company 69.64% owned by SKEL fjárfestingafélag hf., signing a purchase agreement to acquire 100% of the shares in six subsidiaries of Máttarstólpi ehf. The purchase agreement was subject to the approval of the Competition Authority. The transaction was finalized today with payment of purchase price and delivering of shares in the following companies: - Stólpi Gámar ehf., id. 460121-1590, Klettagörðum 5, 104 Reykjavík: - Stólpi Smiðja ehf., id. 460121-1750, Klettagörðum 5, 104 Reykjavík; - Klettskjól ehf., id. 460121-0510, Klettagörðum 5, 104 Reykjavík; - Stólpi ehf., 460121-0430, Klettagörðum 5, 104 Reykjavík; - Tjónaþjónustan ehf., id. 460121-1670, Klettagörðum 5, 104 Reykjavík; - Alkul ehf., id. 491020-0830, Haukdælabraut 48, 113 Reykjavík. collectively referred to as "the sold companies". These companies will continue to be operated on a consolidated basis. The Enterprise value of the sold companie

HiddenA line styled icon from Orion Icon Library.Eye